Wearable Inertial Devices in Duchenne Muscular Dystrophy: A Scoping Review

In clinical practice and research, innovative digital technologies have been proposed for the characterization of neuromuscular and movement disorders through objective measures. Among these, wearable devices prove to be a suitable solution for tele-monitoring, tele-rehabilitation, and daily activities monitoring. Inertial Measurement Units (IMUs) are low-cost, compact, and easy-to-use wearable devices that evaluate kinematics during different movements. Kinematic variables could support the clinical evaluation of the progression of some neuromuscular diseases and could be used as outcome measures. The current review describes the use of IMUs for the biomechanical assessment of meaningful outcome measures in individuals affected by Duchenne muscular dystrophy (DMD). The PRISMA methodology was used and the search was conducted in different databases (Scopus, Web of Science, PubMed). A total of 23 articles were examined and classified according to year of publication, ambulatory/non-ambulatory subjects, and IMU positioning on human body. The analysis points out the recent regulatory identification of Stride Velocity 95th Centile as a new endpoint in therapeutic DMD trials when measured continuously from a wearable device, while only a few studies proposed the use of IMUs in non-ambulatory patients. Clinical recognition of reliable and accurate outcome measures for the upper body is still a challenge.

Automated summary

In clinical practice and research, wearable devices, particularly Inertial Measurement Units (IMUs), have been used for the assessment of neuromuscular and movement disorders through objective measures. This review focuses on the use of IMUs for evaluating meaningful outcome measures in individuals with Duchenne muscular dystrophy (DMD). The analysis highlights the regulatory recognition of Stride Velocity 95th Centile as a new endpoint in therapeutic trials for DMD, as well as the limited use of IMUs in non-ambulatory patients and the challenges in identifying reliable outcome measures for the upper body.